DROIA

DROIA is a specialist investor, exclusively focused on the development of oncology therapies.

DROIA is a specialist investor, exclusively focused on the development of oncology therapies. They are dedicated to making a difference in the fight against cancer. They apply a unique investment model that helps accelerating development within Their portfolio companies, the DROIACs. Through this They aim to bring promising therapies to patients faster, increasing both patient benefit as well as shareholder value. Hence Their name: Double Return On Investment, Accelerated: DROIA DROIA was created in 2011, is funded by private investors, and operates from offices in Luxemburg and Brussels. To day They made 5 investments with immune therapy and tumor cell metabolism as main focus areas within the oncology field. They invest in early stage drug development companies with solid preclinical proof of concept. Their target is to fund Their companies at least up to human proof of concept (phase 1b / 2a). Their investment decisions are driven by research data and based upon the breakthrough potential as expressed by the novelty and potential patient benefit of a candidate therapy.